stockrow
Saturday 7 November 2026
Export LENZ’s income statement to Excel — free account
LENZ Therapeutics, Inc.
LENZ Healthcare Biotechnology
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million.
- Revenue
- −72.9%
- EPS
- −67.1%
- Free cash flow
- −147.2%
Quarter to September 2026, against a year earlier
3.47
0.46
+15.28%
Follow LENZ
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 13.67 | 8.30 | 9.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.96) | (8.54) | (4.60) | (5.41) | |
P/B ratio |
1.62 | 1.16 | 0.81 | 0.63 | |
Price to Tangible BV |
1.62 | 1.16 | 0.81 | 0.63 | |
EV/Sales |
0.00 | 1.46 | (1.84) | (6.02) | |
EV/EBITDA |
0.00 | 0.00 | 0.29 | 0.50 | |
EV/Operating CF |
(2.47) | (0.35) | 0.35 | 0.58 | |
EV/FCF |
(2.44) | (0.35) | 0.35 | 0.58 | |
Quick Ratio |
13.81 | 10.03 | 12.81 | 11.17 | |
Current Ratio |
14.23 | 10.40 | 13.55 | 11.66 | |
Net Debt/EBITDA |
7.62 | 5.87 | 6.46 | 6.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.09 | 0.09 | 0.06 | |
Operating CF/Net income |
0.92 | 0.81 | 1.21 | 0.72 | |
Capex/Depreciation |
(0.36) | (0.16) | (0.15) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2,495.78% | 2,365.07% | 717.79% | 1,059.34% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
231.61% | 227.20% | 81.52% | 122.16% | |
Graham Net Nets |
0.61 | 0.84 | 1.21 | 1.57 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(17.56%) | (39.34%) | (72.01%) | (116.81%) | |
Free Cash Flow Yield |
(15.18%) | (30.48%) | (64.21%) | (105.84%) | |
Revenue per Share |
0.06 | 0.06 | 0.17 | 0.11 | |
Operating CF per Share |
(1.15) | (1.07) | (1.23) | (0.71) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.15) | (1.07) | (1.23) | (0.71) | |
Cash per Share |
10.15 | 8.24 | 7.01 | 6.28 | |
Shareholders Equity per Share |
9.87 | 7.86 | 6.99 | 6.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.87 | 7.86 | 6.99 | 6.11 | |
Free Cash Flow |
(33.06) | (33.60) | (38.73) | (22.31) | |
Working Capital |
280.23 | 242.56 | 216.07 | 189.15 | |
Capital Expenditures |
(0.04) | (0.02) | (0.02) | 0.00 | |
Net Current Asset Value |
279.88 | 242.32 | 215.95 | 189.15 | |
EV/EBIT |
0.00 | 0.00 | 0.29 | 0.50 | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.21 | 7.30 | 4.75 | 4.92 | |
Average Inventory |
— | — | — | 2.85 | |
Average Assets |
260.59 | 236.89 | 226.96 | 210.23 | |
Average Common Equity |
244.21 | 219.25 | 212.81 | 192.96 |
Columns are period end dates · fundamentals updated 5 Nov 2026